Determine whether it’s feasible to cultivate cells from the patient, off the shelf cells from human sources, or xeno-sourced cells. What are the survivability and stress tolerance standards that cells must meet to be seriously considered as a possibility?
Identify methods of scaling up cardiomyocyte production from pluripotent stem cell differentiation. How can we mass produce hiPSC-CMs in a reactor-based format that incorporates self-selection to purify cardiomyocytes during the differentiation process?
Identify novel cell surface markers for stem cell-derived cardiomyocytes that can allow for the specific identification, selection, and sorting of cardiomyocytes during the cardiomyocyte differentiation process from stem cells.
Identify other support cells that may be important for hiPSC-CM function. Besides hiPSC-CMs and endothelial cells, what is the role of other cell types that should be potentially incorporate (i.e. fibroblasts, pericytes, smooth muscle cells, mesenchymal stem cells)